Total cholesterol (CHOL) levels have been shown in many studies, to be higher in people with several types of cancer. Similar results are observed for both triglycerides (TG) and low-density cholesterol (LDL), as opposed to high-density cholesterol (HDL). Chemotherapy seems to reduce CHOL and LDL, leading to a reduction. Furthermore, the recurrence of high levels of CHOL, TG and LDL, as well as low levels of HDL, after receiving treatment, or when patients appear to have been cured, are signs of a possible recurrence of the disease. Lipoprotein α (Lpa), occurs at higher levels in patients than in healthy people, whereas lipokines resistin and bisfatin, “hormonal” products of adipose tissue exhibited high levels in cancer cases, compared to control groups.
Large, V., Peroni, O., Letexier, D., Ray, H. and Beylot, M. (2004) Metabolism of Lipids in Human White Adipocyte. Diabetes & Metabolism, 30, 294-309. https://doi.org/10.1016/S1262-3636(07)70121-0
Wolin, K.Y., Carson, K. and Colditz, G.A. (2010) Obesity and Cancer. Oncologist, 15, 556-565. https://doi.org/10.1634/theoncologist.2009-0285
Vance, J.E. and Vance, D. (2008) Biochemistry of Lipids, Lipoproteins and Membranes. 5th Edition, Elsevier, Amsterdam, 8-9.
Mattes, R.D. (2005) Fat Taste and Lipid Metabolism in Humans. Physiology & Behavior, 86, 691-697. https://doi.org/10.1016/j.physbeh.2005.08.058
Zechner, R., Zimmermann, R., Eichmann, T.O., Kohlwein, S.D., Haemmerle, G., Lass, A. and Madeo, F. (2012) Fat Signals—Lipases and Lipolysis in Lipid Metabolism and Signaling. Cell Metabolism, 15, 279-291. https://doi.org/10.1016/j.cmet.2011.12.018
Fahy, E., Cotter, D., Sud, M. and Subramaniam, S. (2011) Lipid Classification, Structures and Tools. Biochim et Biophys Acta: Molecular and Cell Biology of Lipids, 1811, 637-647. https://doi.org/10.1016/j.bbalip.2011.06.009
Santos, C.R. and Schulze, A. (2012) Lipid Metabolism in Cancer. The FEBS Journal, 279, 2610-2623. https://doi.org/10.1111/j.1742-4658.2012.08644.x
Hsu, P.P. and Sabatini, D.M. (2008) Cancer Cell Metabolism: Warburg and Beyond. Cell, 134, 703-707. https://doi.org/10.1016/j.cell.2008.08.021
Menendez, J.A. and Lupu, R. (2007) Fatty Acid Synthase and the Lipogenic Phenotype in Cancer Pathogenesis. Nature Reviews Cancer, 7, 763-777. https://doi.org/10.1038/nrc2222
Zaidi, N., Lupien, L., Kuemmerle, N.B., Kinlaw, W.B., Swinnen, J.V. and Smans, K. (2013) Lipogenesis and Lipolysis: The Pathways Exploited by the Cancer Cells to Acquire Fatty Acids. Progress in Lipid Research, 52, 585-589. https://doi.org/10.1016/j.plipres.2013.08.005
Grundy, S.M. (2004) Obesity, Metabolic Syndrome, and Cardiovascular Disease. The Journal of Clinical Endocrinology & Metabolism, 89, 2595-2600. https://doi.org/10.1210/jc.2004-0372
Munir, R., Usman, H., Hasnain, S., Smans, K., Kalbacher, H. and Zaidi, N. (2014) Atypical Plasma Lipid Profile in Cancer Patients: Cause or Consequence. Biochinie, 102, 9-18. https://doi.org/10.1016/j.biochi.2014.03.010
Serum Lipids and Lipokines as Prognostic/Diagnostic Biomarkers in Common Cancers — Oak Academic Publishing
Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008) Cancerrelated Inflammation. Nature, 454, 436-444. https://doi.org/10.1038/nature07205
Coussens, L.M. and Werb, Z. (2002) Inflammation and Cancer. Nature, 420, 860-867. https://doi.org/10.1038/nature01322
Alexandrov, L.B., Nik-Zainal, S., Wedge, D., Aparicio, S.A., Behjati, S., Biankin, A.V., et al. (2013) Signatures of Mutational Processes in Human Cancer. Nature, 500, 415-421. https://doi.org/10.1038/nature12477
Iyengar, N.M., Hudis, C.A. and Dannenberg, A.J. (2015) Obesity and Cancer: Local and Systemic Mechanisms. Annual Review of Medicine, 66, 297-309. https://doi.org/10.1146/annurev-med-050913-022228
Lengauer, C., Kinzler, K.W. and Vogelstein, B. (1998) Genetic Instabilities in Human Cancers. Nature, 396, 643-649. https://doi.org/10.1038/25292
Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., et al. (2011) Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development. Cell, 144, 27-40.
Sansregret, L., Vanhaesebroeck, B. and Swanton, C. (2018) Determinants and Clinical Implications of Chromosomal Instability in Cancer. Nature Reviews Clinical Oncology, 15, 139-150. https://doi.org/10.1038/nrclinonc.2017.198
Jain, R.K. (2005) Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science, 307, 58-62. https://doi.org/10.1126/science.1104819
Minchinton, A.I. and Tannock, I.F. (2006) Drug Penetration in Solid Tumours. Nature Reviews Cancer, 6, 583-592. https://doi.org/10.1038/nrc1893
Goldie, J.H. and Coldman, A.J. (1984) The Genetic Origin of Drug Resistance in Neoplasms: Implications for Systemic Therapy. Cancer Research, 44, 3643-3653.
Fisher, B., Slack, N.H. and Bross, I.D. (1969) Cancer of the Breast: Size of Neoplasm and Prognosis. Cancer, 24, 1071-1080. https://doi.org/10.1002/1097-0142(196911)24:5 3.0.CO;2-H
Skipper, H.E., Schabel Jr., F.M. and Wilcox, W.S. (1964) Experimental Evaluation of Potential Anticancer Agents. XIII. On the Criteria and Kinetics Associated with “Curability” of Experimental Leukemia. Cancer Chemotherapy Reports, 35, 1-111.
Sharma, P., Hu-Lieskovan, S., Wargo, J.A. and Ribas, A. (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 168, 707-723. https://doi.org/10.1016/j.cell.2017.01.017
Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., et al. (2008) Modelling Myc Inhibition as a Cancer Therapy. Nature, 455, 679-683. https://doi.org/10.1038/nature07260
Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A. and Shokat, K.M. (2013) K-Ras(G12C) Inhibitors Allosterically Control GTP Affinity and Effector Interactions. Nature, 503, 548-551. https://doi.org/10.1038/nature12796
Lambert, J.M., Gorzov, P., Veprintsev, D.B.,Söderqvist, M., Segerbäck, D., Bergman, J., et al. (2009) PRIMA-1 Reactivates Mutant P53 by Covalent Binding to the Core Domain. Cancer Cell, 15, 376-388. https://doi.org/10.1016/j.ccr.2009.03.003
Timovska, Y., Pivnyuk, V., Todor, I., Anikusko, N. and Chekhun, V. (2011) The Spectrum of Blood Serum Lipids in Patients with Breast Cancer without Metabolic Syndrome. Experimental Oncology, 33, 190-192.
Agurs-Collins, T., Kim, K.S., Dunston, G.M. and Adams-Campbell, L.L. (1998) Plasma Lipid Alterations in African-American Women with Breast Cancer. Journal of Cancer Research and Clinical Oncology, 124, 186-190. https://doi.org/10.1007/s004320050153
Delimaris, I., Faviou, E., Antonakos, G., Stathopoulou, E., Zachari, A. and Dionyssiou-Asteriou, A. (2007) Oxidized LDL, Serum Oxidizability and Serum Lipid Levels in Patients with Breast or Ovarian Cancer. Clinical Biochemistry, 40, 1129-1134. https://doi.org/10.1016/j.clinbiochem.2007.06.007
Abdelsalam, K.E., Hassan, I.K. and Sadig, I.A. (2012) The Role of Developing Breast Cancer in Alteration of Serum Lipid Profile. Journal of Research in Medical Sciences 17, 562-565.
Bhat, S.A., Mir, M.R., Majid, S., Reshi, A.A., Husain, I., Hassan, T. and Ahmad, H. (2013) Serum Lipid Profile of Breast Cancer Patients in Kashmir. American Journal of Physiology, Biochemistry and Pharmacology, 2, 26-31. https://doi.org/10.5455/jib.20121125075314
Hasija, K. and Bagga, H.K. (2005) Alterations of Serum Cholesterol and Serum Lipoprotein in Breast Cancer of Women. Indian Journal of Clinical Biochemistry, 20, 61-66. https://doi.org/10.1007/BF02893044
Liu, Y.L., Qian, H.X., Qin, L., Zhou, X.J., Zhang, B. and Chen, X. (2012) Association of Serum Lipid Profile with Distant Metastasis in Breast Cancer Patients. Chinese Journal of Oncology, 34, 129-131
Bahl, M., Ennis, M., Tannock, I.F., Hux, J.E., Pritchard, K.I., Koo, J. and Goodwin, P.J. (2005) Serum Lipids and Outcome of Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Breast Cancer Research and Treatmen, 94, 135-144. https://doi.org/10.1007/s10549-005-6654-9
Eliassen, A.H., Colditz, G.A., Rosner, B., Willett, W.C. and Hankinson, S.E. (2005) Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer. Archives of Internal Medicine, 165, 2264-2271. https://doi.org/10.1001/archinte.165.19.2264
Thangaraju, M., Kumar, K., Gandhirajan, R. and Sachdanandam, P. (1994) Effect of Tamoxifen on Plasma Lipids and Lipoproteins in Postmenopausal Women with Breast Cancer. Cancer, 73, 659-663. https://doi.org/10.1002/1097-0142(19940201)73:3 3.0.CO;2-H
Knapp, M., Al-Sheibani, S. and Riches, P. (1991) Alterations of Serum Lipids in Breast Cancer: Effects of Disease Activity, Treatment, and Hormonal Factors. Clinical Chemistry, 37, 2093-2101. https://doi.org/10.1093/clinchem/37.12.2093
Hoyer, A.P. and Engholm, G. (1992) Serum Lipids and Breast Cancer Risk: A Cohort Study of 5,207 Danish Women. Cancer Causes & Control, 3, 403-408. https://doi.org/10.1007/BF00051352
Laisupasin, P., Thompat, W., Sukarayodhin, S., Sornprom, A. and Sudjaroen, Y. (2013) Comparison of Serum Lipid Profiles between Normal Controls and Breast Cancer Patients. Journal of Laboratory Physicians, 5, 38-41. https://doi.org/10.4103/0974-2727.115934
Furberg, A.S., Jasienska, G., Bjurstam, N., Torjesen, P.A., Emaus, A., Lipson, S.F., Ellison, P.T. and Thune, I. (2005) Metabolic and Hormonal Profiles: HDL Cholesterol as a Plausible Biomarker of Breast Cancer Risk. Cancer Epidemiology, Biomarkers & Prevention, 14, 33-40.
Furberg, A.S., Veierod, M.B., Wilsgaard, T., Bernstein, L. and Thune, I. (2004) Serum Highdensity Lipoprotein Cholesterol, Metabolic Profile, and Breast Cancer Risk. JNCI: Journal of the National Cancer Institute, 96, 1152-1160. https://doi.org/10.1093/jnci/djh216
Lindemann, K., Vatten, L.J., Ellstrom-Engh, M. and Eskild, A. (2009) Serum Lipids and Endometrial Cancer Risk: Results from the HUNT-II Study. International Journal of Cancer, 124, 2938-2941. https://doi.org/10.1002/ijc.24285
Seth, D., Garmo, H., Wigertz, A., Holmberg, L., Hammar, N., Jungner, I., Lambe, M., Walldius, G. and Van Hemelrijck, M. (2012) Lipid Profiles and the Risk of Endometrial Cancer in the Swedish AMORIS Study. International Journal of Molecular Epidemiology and Genetics, 3, 122-133.
Allott, E., Howard, L., Cooperberg, M.R., Kane, C., Aronson, W.J., Terris, M., Amling, C. and Freedland, S. (2014) Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiology, Biomarkers & Prevention, 23, 2349-2356. https://doi.org/10.1158/1055-9965.EPI-14-0458
Salgado-Montilla, J., Salgado, M., Trautmann, B., Sánchez-Ortiz, R. and Irizarry-Ramírez, M. (2015) Association of Serum Lipid Levels and Prostate Cancer Severity among Hispanic Puerto Rican Men. Lipids in Health and Disease, 14, Article No. 111. https://doi.org/10.1186/s12944-015-0096-0
Zhang, G., Qin, X.J., Zhang, H.L., Xiao, W.J., Zhu, Y., Gu, C.Y., Dai, B., Shi, G.H. and Ye, D.W. (2015) Serum Lipid Profiles: Novel Biomarkers Predicting Advanced Prostate Cancer in Patients Receiving Radical Prostatectomy. Asian Journal of Andrology, 17, 239-244. https://doi.org/10.4103/1008-682X.142135
Qiming, S.C., Ding, Z.G. and Li, G. (2019) Influence of Serum Total Cholesterol, LDL, HDL, and Triglyceride on Prostate Cancer Recurrence after Radical Prostatectomy. Cancer Management and Research, 11, 6651-6661. https://doi.org/10.2147/CMAR.S204947
Siemianowicz, K., Gminski, J., Stajszczyk, M., Wojakowski, W., Goss, M., Machalski, M., Telega, A., Brulinski, K. and Magiera-Molendowska, H. (2000) Serum HDL Cholesterol Concentration in Patients with Squamous Cell and Small Cell Lung Cancer. International Journal of Molecular Medicine, 6, 307-318. https://doi.org/10.3892/ijmm.6.3.307
Siemianowicz, K., Gminski, J., Stajszczyk, M., Wojakowski, W., Goss, M., Machalski, M., Telega, A., Brulinski, K. and Magiera-Molendowska, H. (2000) Serum Total Cholesterol and Triglycerides Levels in Patients with Lung Cancer. International Journal of Molecular Medicine, 5, 201-205. https://doi.org/10.3892/ijmm.5.2.201
Siemianowicz, K., Gminski, J., Stajszczyk, M., Wojakowski, W., Goss, M., Machalski, M., Telega, A., Brulinski, K. and Magiera-Molendowska, H. (2000) Serum LDL Cholesterol Concentration and Lipoprotein Electrophoresis Pattern in Patients with Small Cell Lung Cancer. International Journal of Molecular Medicine, 5, 55-62. https://doi.org/10.3892/ijmm.5.1.55
Zhan, C.-Z., Zhao, X.-W., Liu, D.-B., Han, C.-Z., Du, L.-L. and Jing, J.-X. (2014) Lipid Levels in Serum and Cancerous Tissues of Colorectal Cancer Patients. World Journal of Gastroenterology, 20, 8646-8652. https://doi.org/10.3748/wjg.v20.i26.8646
Iso, H., Ikeda, A., Inoue, M., Sato, S. and Tsugane, S. (2009) Serum Cholesterol Levels in Relation to the Incidence of Cancer: The JPHC Study Cohorts. International Journal of Cancer, 125, 2679-2686. https://doi.org/10.1002/ijc.24668
Brantleya, K., Riisc, A., Erichsenc, R., Thorlacius-Ussinge, O., Jon Møllerf, H. and Lasha, T. (2020) the Association of Serum Lipid Levels with Colorectal Cancer Recurrence. Cancer Epidemiology, 66, Article ID: 101725. https://doi.org/10.1016/j.canep.2020.101725
Chandler, P.D., Song, Y., Lin, L., Zhang, S., Sesso, H.D. and Mora, S. (2016) Lipid Biomarkers and Long-Term Risk of Cancer in the Women’s Health Study. The American Journal of Clinical Nutrition, 6, 1397-1407. https://doi.org/10.3945/ajcn.115.124321
Yang, M.H., Rampal, S., Sung, J., Choi, Y.-H., Son, H.J., Lee, J.H., Kim, Y.H., Chang, D.K., Rhee, P-L. and Kim, J.J. (2013) the Association of Serum Lipids with Colorectal Adenomas. American Journal of Gastroenterology, 108, 833-841. https://doi.org/10.1038/ajg.2013.64
Lippi, G., Franchini, M., Salvagno, G.L. and Guidi, G.C. (2007) Lipoprotein[a] and Cancer: Anti-Neoplastic Effect besides Its Cardiovascular Potency. Cancer Treatment Reviews, 33, 427-436. https://doi.org/10.1016/j.ctrv.2007.02.006
Leibundgut, G., Scipione, C., Yin, H., Schneider, M., Boffa, M.B., Green, S., Yang, X., Dennis, E., Witztum, J.L., Koschinsky, M.L. and Tsimikas, S. (2013) Determinants of Binding of Oxidized Phospholipids on Apolipoprotein (a) and Lipoprotein (a). Journal of Lipid Research, 54, 2815-2830. https://doi.org/10.1194/jlr.M040733
Orso, E. and Schmitz, G. (2017) Lipoprotein(a) and Its Role in Inflammation, Atherosclerosis and Malignancies. Clinical Research in Cardiology Supplements, 12, 31-37. https://doi.org/10.1007/s11789-017-0084-1
Constans, J., Wendling, G., Peuchant, E., Camilleri, G. and Conri, C. (1996) Lipoprotein(a) in 505 Hospitalized Patients with Various Pathological States: Correlations with Cardiovascular Diseases and Therapies. International Angiology, 15, 1-5.
Wang, M. and Zhang, Y. (2019) High Lipoprotein(a) Level Is Independently Associated with Adverse Clinicopathological Features in Patients with Prostate. Dis Markers, 2019, Article ID: 9483935. https://doi.org/10.1155/2019/9483935
Marrera, M., Wagnera, A., Le Montayed, M., Luce, G., Amouyel, P., Dallongeville, J., Ducimetiere, P., Bingham, A., Arveiler, D. and Veltena, M. (2013) Lipoprotein(a) Plasma Levels and the Risk of Cancer: The PRIME Study. European Journal of Cancer Prevention, 22, 286-293. https://doi.org/10.1097/CEJ.0b013e328359cba7
Motta, M., Giugno, I., Ruello, P., Pistone, G., Di Fazio, I. and Malaguarnera, M. (2001) Lipoprotein(a) Behaviour in Patients with Hepatocellular Carcinoma. Minerva Medica, 92, 301-305.
Jiang, J., Nilsson-Ehle, P. and Xu, N. (2006) Influence of Liver Cancer on Lipid and Lipoprotein Metabolism. Lipids in Health and Disease, 5, Article No. 4. https://doi.org/10.1186/1476-511X-5-4
Xu, J., Qiu, X., Li, Y., Sun, N., Zhang, Y. and Shu, J. (2020) Hyperlipoproteinemia (a) Is Associated with Breast Cancer in a Han Chinese Population. Medicine, 99, Article No. e22037. https://doi.org/10.1097/MD.0000000000022037
Sawabe, M., Tanaka, N. and Mieno, M.N. (2012) Low Lipoprotein(a) Concentration Is Associated with Cancer and All-Cause Deaths: A Population-Based Cohort Study. PLoS ONE, 7, Article ID: e31954. https://doi.org/10.1371/journal.pone.0031954
Kokoglu, E., Karaarslan, I. and Karaarslan, H.M. (1994) Elevated Serum Lp(a) Levels in the Early and Advanced Stages of Breast Cancer. Cancer Biochemistry Biophysics, 14, 133-136.
Kuesel, A.C., Kroft, T., Prefontaine, M. and Smith, I.C. (1992) Lipoprotein(a) and CA125 Levels in the Plasma of Patients with Benign and Malignant Ovarian Disease. International Journal of Cancer, 52, 341-346. https://doi.org/10.1002/ijc.2910520302
Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S. and Lazar, M.A. (2001) the Hormone Resistin Links Obesity to Diabetes. Nature, 409, 307-312. https://doi.org/10.1038/35053000
Savage, D.B., Sewter, C.P., Klenk, E.S., Segal, D.G., Vidal-Puig, A., Considine, R.V. and O’Rahilly, S. (2001) Resistin/Fizz3 Expression in Relation to Obesity and Peroxisome Proliferator-Activated Receptor-γ Action in Humans. Diabetes, 50, 2199-2202. https://doi.org/10.2337/diabetes.50.10.2199
Lehrke, M., Reilly, M.P., Millington, S.C., Iqbal, N., Rader, D.J. and Lazar, M.A. (2004) An Inflammatory Cascade Leading to Hyperresistinemia in Humans. PLoS Medicine, 1, Article No. e45. https://doi.org/10.1371/journal.pmed.0010045
Danese, E., Montagnana, M., Minicozzi, A.M., Bonafini, S., Ruzzenente, O., Gelati, M., De Manzoni, G., Lippi, G. and Guidi, G.C. (2012) The Role of Resistin in Colorectal Cancer. Clinica Chimica Acta, 413, 760-764. https://doi.org/10.1016/j.cca.2012.01.019
Assiri, A.M., Kamel, H.F. and Hassanien, M.F. (2015) Resistin, Visfatin, Adiponectin, and Leptin: Risk of Breast Cancer in Pre- and Postmenopausal Saudi Females and Their Possible Diagnostic and Predictive Implications as Novel Biomarkers. Disease Markers, 2015, Article ID: 253519, 9 Pages. https://doi.org/10.1155/2015/253519
Assiri, A.M. and Kamel, H.F. (2016) Evaluation of Diagnostic and Predictive Value of Serum Adipokines: Leptin, Resistin and Visfatin in Postmenopausal Breast Cancer. Obesity Research & Clinical Practice, 10, 442-453. https://doi.org/10.1016/j.orcp.2015.08.017
Kang, J.H., Yu, B.Y. and Youn, D.S. (2007) Relationship of Serum Adiponectin and Resistin Levels with Breast Cancer Risk. Journal of Korean Medical Science, 22, 117-121. https://doi.org/10.3346/jkms.2007.22.1.117
Dalamaga, M., Karmaniolas, K., Papadavid, E., Pelekanos, N., Sotiropoulos, G. and Lekka, A. (2013) Hyperresistinemia Is Associated with Postmenopausal Breast Cancer. Menopause, 20, 845-851. https://doi.org/10.1097/GME.0b013e31827f06dc
Gunter, M.J., Wang, T., Cushman, M., Xue, X., Wassertheil-Smoller, S., Strickler, H.D., Rohan, T.E., Manson, J.E., McTiernan, A., Kaplan, R.C., Scherer, P.E., Chlebowski, R.T., Snetselaar, L., Wang, D. and Ho, G.Y. (2015) Circulating Adipokines and Inflammatory Markers and Postmenopausal Cancer Risk. JNCI: Journal of the National Cancer Institute, 107, djv169. https://doi.org/10.1093/jnci/djv169
Mu~noz-Palomeque, A., Guerrero-Ramirez, M.A., Rubio-Chavez, L.A., Rosales-Gomez, R.C., Lopez-Cardona, M.G., Barajas-Avila, V.H., Delgadillo-Barrera, A., Canton-Romero, J.C., Montoya-Fuentes, H., Garcia-Cobian, T.A. and Gutierrez-Rubio, S.A. (2018) Association of RETN and CAP1 SNPs, Expression and Serum Resistin Levels with Breast Cancer in Mexican Women. Genetic Testing and Molecular Biomarkers, 22, 209-217. https://doi.org/10.1089/gtmb.2017.0212
Crisostomo, P., Matafome, D., Santos-Silva, A.L., Gomes, M., Gomes, M., Patricio, L., Letra, A.B., Sarmento-Ribeiro, L. and Seica, S.R. (2016) Hyperresistinemia and Metabolic Dysregulation: A Risky Crosstalk in Obese Breast Cancer. Endocrine, 53, 433-442. https://doi.org/10.1007/s12020-016-0893-x
Salageanu, A., Tucureanu, C. and Lerescu, L. (2010) Serum Levels of Adipokines Resistin and Leptin in Patients with Colon Cancer. Journal of Medicine and Life, 3, 416-420.
Nakajima, T.E., Yamada, Y. and Hamano, T. (2010) Adipocytokines as New Promising Markers of Colorectal Tumors: Adiponectin for Colorectal Adenoma, and Resistin and Visfatin for Colorectal Cancer. Cancer Science, 101, 1286-1291. https://doi.org/10.1111/j.1349-7006.2010.01518.x
Gonullu, G., Kahraman, H., Bedir, A., Bektas, A. and Yucel, I. (2010) Association between Adiponectin, Resistin, Insulin Resistance, and Colorectal Tumors. International Journal of Colorectal Disease, 25, 205-212. https://doi.org/10.1007/s00384-009-0828-6
Diakowska, D., Markocka-Mdczka, K., Szelachowski, P. and Grabowski, K. (2014) Serum Levels of Resistin, Adiponectin, and Apelin in Gastroesophageal Cancer Patients. Disease Markers, 2014, Article ID: 619649. https://doi.org/10.1155/2014/619649
Samal, B., Sun, Y., Stearns, G., Xie, C., Suggs, S. and McNiece, I. (1994) Cloning and Characterization of the CDNA Encoding a Novel Human Pre-B-Cell Colony-Enhancing Factor. Molecular and Cellular Biology, 14, 1431-1437. https://doi.org/10.1128/mcb.14.2.1431-1437.1994
Preiss, J. and Handler, P. (1957) Enzymatic Synthesis of Nicotinamide Mononucleotide. Journal of Biological Chemistry, 225, 759-770. https://doi.org/10.1016/S0021-9258(18)64875-6
Rongvaux, A., Shea, R.J., Mulks, M.H., Gigot, D., Urbain, J., Leo, O. and Andris, F. (2002) Pre-B-Cell Colony-Enhancing Factor, Whose Expression Is Up-Regulated in Activated Lymphocytes, Is a Nicotinamide Phosphoribosyltransferase, a Cytosolic Enzyme Involved in NAD Biosynthesis. European Journal of Immunology, 32, 3225-3234. https://doi.org/10.1002/1521-4141(200211)32:11 3.0.CO;2-L
Luk, T., Malam, Z. and Marshall, J.C. (2008) Pre-B Cell Colony-Enhancing Factor (PBEF)/Visfatin: A Novel Mediator of Innate Immunity. Journal of Leukocyte Biology, 83, 804-816. https://doi.org/10.1189/jlb.0807581
Murphy, K.G. and Bloom, S.R. (2006) Are All Fats Created Equal. Nature Medicine, 12, 32-33. https://doi.org/10.1038/nm0106-32
Revollo, J.R., Grimm, A.A. and Imai, S. (2004) the NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells. Journal of Biological Chemistry, 279, 50754-50763. https://doi.org/10.1074/jbc.M408388200
Curat, C.A., Wegner, V., Sengenes, C., Miranville, A., Tonus, C., Busse, R. and Bouloumie, A. (2006) Macrophages in Human Visceral Adipose Tissue: Increased Accumulation in Obesity and a Source of Resistin and Visfatin. Diabetologia, 49, Article No. 744. https://doi.org/10.1007/s00125-006-0173-z
Boucher, J., Masri, B., Daviaud, D., Gesta, S., Guigne, C., Mazzucotelli, A., Castan-Laurell, I., Tack, I., Knibiehler, B., Carpene, C., Audigier, Y., Saulnier-Blache, J.S. and Valet, P. (2005) Apelin, a Newly Identified Adipokine Up-Regulated by Insulin and Obesity. Endocrinology, 146, 1764-1771. https://doi.org/10.1210/en.2004-1427
Berndt, J., Kloting, N., Kralisch, S., Kovacs, P., Fasshauer, M., Schon, M.R., Stumvoll, M. and Bluher, M. (2005) Plasma Visfatin Concentrations and Fat Depot-Specific MRNA Expression in Humans. Diabetes, 54, 2911-2916. https://doi.org/10.2337/diabetes.54.10.2911
Dalamaga, M., Karmaniolas, K., Papadavid, E., Pelekanos, N., Sotiropoulos, G. and Lekka, A. (2011) Elevated Serum Visfatin/nicotinamide Phosphoribosyl-Transferase Levels Are Associated with Risk of Postmenopausal Breast Cancer Independently from Adiponectin, Leptin, and Anthropometric and Metabolic Parameters. Menopause, 18, 1198-1204. https://doi.org/10.1097/gme.0b013e31821e21f5
Dalamaga, M., Archondakis, S., Sotiropoulos, G., Karmaniolas, K., Pelekanos, N., Papadavid, E. and Lekka, A. (2012) Could Serum Visfatin Be a Potential Biomarker for Postmenopausal Breast Cancer. Maturitas, 71, 301-308. https://doi.org/10.1016/j.maturitas.2011.12.013
Li, X.Y., Tang, S.H., Zhou, X.C., Ye, Y.H., Xu, X.Q. and Li, R.Z. (2014) Preoperative Serum Visfatin Levels and Prognosis of Breast Cancer among Chinese Women. Peptides, 51, 86-90. https://doi.org/10.1016/j.peptides.2013.11.010
Hung, A.C., Lo, S., Hou, M.F., Lee, Y.C., Tsai, C.H., Chen, Y.Y., Liu, W., Su, Y.H., Lo, Y.H., Wang, C.H., Wu, S.C., Hsieh, Y.C., Hu, S.C., Tai, M.H., Wang, Y.M. and Yuan, S.S. (2016) Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through C-Abl and STAT3 Activation. Clinical Cancer Research, 22, 4478-4490. https://doi.org/10.1158/1078-0432.CCR-15-2704
Zhu, Y., Guo, M., Zhang, L., Xu, T., Wang, L. and Xu, G. (2016) Biomarker Triplet NAMPT/ VEGF/HER2 as a De Novo Detection Panel for the Diagnosis and Prognosis of Human Breast Cancer. Oncology Reports, 35, 454-462. https://doi.org/10.3892/or.2015.4391
Rodrigo, C., Tennekoon, K.H., Karunanayake, E.H., De Silva, K., Amarasinghe, I. and Wijayasiri, A. (2017) Circulating Leptin, Soluble Leptin Receptor, Free Leptin Index, Visfatin and Selected Leptin and Leptin Receptor Gene Polymorphisms in Sporadic Breast Cancer. Endocrine Journal, 64, 393-401. https://doi.org/10.1507/endocrj.EJ16-0448
Cymbaluk-PBoska, A., Chudecka-GBaz, A., Pius-Sadowska, E., Sompolska-RzechuBa, A., MachaliNski, B. and Menkiszak, J. (2018) Circulating Serum Level of Visfatin in Patients with Endometrial Cancer. BioMed Research International, January, 2018, Article ID: 8576179. https://doi.org/10.1155/2018/8576179
Ilhan, T., Kebapcilar, A. and Yilmaz, S. (2015) Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with Its Prognosis. Asian Pacific Journal of Cancer Prevention, 16, 4503-4508. https://doi.org/10.7314/APJCP.2015.16.11.4503
Avcioglu, S., Altinkaya, S., Küçük, M., Yüksel, H., Ömürlü, I. and Yanik, S. (2015) Visfatin Concentrations in Patients with Endometrial Cancer. Gynecological Endocrinology, 31, 202-207. https://doi.org/10.3109/09513590.2014.975687
Tian, W., Zhu, Y. and Wang, Y. (2013) Visfatin, a Potential Biomarker and Prognostic Factor for Endometrial Cancer. Gynecologic Oncology, 129, 505-512. https://doi.org/10.1016/j.ygyno.2013.02.022
Tian, W.Y., Wang, Y.M., Zhang, Y.F. and Xue, F.X. (2017) The Research Advances in the Relationship between Visfatin and Cancer. Chinese Journal of Oncology, 39, 321-324.
Fazeli, M.S., Dashti, H., Akbarzadeh, S., Assadi, M., Aminian, A., Keramati, M.R. and Nabipour, I. (2013) Circulating Levels of Novel Adipocytokines in Patients with Colorectal Cancer. Cytokine, 62, 81-85. https://doi.org/10.1016/j.cyto.2013.02.012
Sun, Y., Zhu, S., Wu, Z., Huang, Y., Liu, C., Tang, S. and Wei, L. (2017) Elevated Serum Visfatin Levels Are Associated with Poor Prognosis of Hepatocellular Carcinoma. Oncotarget, 8, 23427-23435. https://doi.org/10.18632/oncotarget.15080
Ninomiya, S., Shimizu, M., Imai, K., Takai, K., Shiraki, M., Hara, T., Tsurumi, H., Ishizaki, S. and Moriwaki, H. (2011) Possible Role of Visfatin in Hepatoma Progression and the Effects of Branched-Chain Amino Acids on Visfatin-Induced Proliferation in Human Hepatoma Cells. Cancer Prevention Research, 4, 2092-2100. https://doi.org/10.1158/1940-6207.CAPR-11-0340
Luhn, P., Dallal, C. and Weiss, J. (2013) Circulating Adipokine Levels and Endometrial Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiology, 22, 1304-1312. https://doi.org/10.1158/1055-9965.EPI-13-0258
Lu, G.W., Wang, Q.J., Xia, M.M. and Qian, J. (2014) Elevated Plasma Visfatin Levels Correlate with Poor Prognosis of Gastric Cancer Patients. Peptides, 58, 60-64. https://doi.org/10.1016/j.peptides.2014.05.016
Sourra, E.N., Sevastou, A., Villiotou, V. and Karikas, G.A. (2015) Correlation of Serum Lipid Concentrations in Patients with Acute Lymphoblastic Leukemia. Epitheorisi Klinikes Farmacologias Kai Farmakokinetikis, 33, 25.